SRAD vs XTLB Stock Comparison

Sportradar Group AG and Xtl Biopharmaceuticals Prices as of Oct 26, 2026 Peers: Industry group
SRAD Sportradar Group AG
$12.60 -4.8% 1M -53.4% 1Y
Market cap
$12.65B
P/E
634.4x
Revenue (TTM)
$1.62B
Div. yield
–
Data Infrastructure Technology
4 wins

Head to Head

4 decided of 12

Sportradar Group AG leads on 4 of the 12 questions below (Sportradar Group AG 4). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionSRADXTLBLeader
Larger companyMarket capitalisation $12.65B $16.22M SRAD
Cheaper on earningsLower P/E, profitable companies only 634.4x -2.3x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 48.5x — –
Faster revenue growthRevenue growth, trailing twelve months +24.7% — –
More profitableNet margin, trailing twelve months 1.2% — –
Better return on capitalReturn on invested capital -8.6% — –
Less leveragedLower net debt / EBITDA 1.4x — –
Higher dividend yieldTrailing dividend yield 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -53.4% -63.0% SRAD
Better 5-year returnAnnualised price return, 5 years -9.0%/yr -34.6%/yr SRAD
Less volatileAnnualised volatility, 1 year 56.6% 108.9% SRAD
Higher overall scoreMean of the five percentile scores vs peers 59/100 — –

Percentile Scorecard

SRADXTLB

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisSRADXTLB
Valuation 77 #29 of 124 25 #473 of 626
Growth 63 #43 of 113 –
Profitability 71 #33 of 110 –
Financial Health 56 #57 of 129 2 #644 of 658
Shareholder Returns 30 #47 of 67 –
Overall 59 –
  • SRAD ranked among 137 companies in Infrastructure Software
  • XTLB ranked among 673 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodSRADXTLBSPY
1 month -4.8%-19.1% -0.8%
3 months -14.2%-36.8% +3.5%
6 months -9.5%-23.8% +7.0%
Year to date -47.0%-21.6% +12.2%
1 year -53.4%-63.0% +13.0%
3 years +44.0%-44.5% +86.3%
3 years, per year +12.9%-17.8% +23.1%
5 years -37.5%-88.0% +68.6%
5 years, per year -9.0%-34.6% +11.0%
10 years —-89.5% +258.0%
10 years, per year —-20.2% +13.6%

Risk

MeasureSRADXTLBSPY
Volatility, 1Y 56.6%108.9% 12.7%
Downside volatility, 1Y 64.4%90.6% 12.7%
Beta vs S&P 500, 1Y 0.570.54 1.00
Return / volatility, 1Y -0.94-0.58 1.02
Max drawdown, 5Y -69.0%-88.9% -25.4%
From 52-week high -53.5%-62.1% -1.8%
52-week high $27.11$4.80 $779.14
52-week low $11.56$1.78 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleSRADXTLB
P/E now vs peer median 655.2xmedian 38.1x -2.3xmedian 17.1x
P/S now vs peer median 2.4xmedian 4.3x 2,460xmedian 8.8x
EV/EBITDA now vs peer median -14.4xmedian 35.4x —median 17.1x
P/FCF now vs peer median 7.7xmedian 27.1x -16.8xmedian 18.0x
P/B now vs peer median 4.4xmedian 3.4x -67.8xmedian 2.1x
PEG now vs peer median 22.63median 1.27 —median 0.31

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsSRADXTLB
Revenue $1.62B –
Net income $19.94M –
Free cash flow $510.26M –
R&D $44.37M –
EPS (diluted) $64,328.88 –
Cash & equivalents $286.82M $76.00K
Total debt $49.28M $530.00K
Shares (diluted) 310.00 8.96M
Enterprise value $10.94B $13.02M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricSRADXTLB
P/E 655.2x -2.3x
P/FCF 7.7x -16.8x
P/Operating cash flow 7.8x –
P/S 2.4x 2,460x
P/B 4.4x -67.8x
P/Tangible book 4.4x -67.8x
EV/EBITDA -14.4x –
EV/EBIT -42.7x –
EV/Revenue 2.2x –
EV/FCF 7.0x –
EV/Operating cash flow 7.2x –
PEG (3Y EPS CAGR) 22.63 –

Growth

14 metrics
MetricSRADXTLB
Revenue growth (1Y) 24.7% –
Revenue CAGR (3Y) 23.9% –
Gross profit growth (1Y) – –
Gross profit CAGR (3Y) – –
Operating income growth (1Y) – –
Operating income CAGR (3Y) – –
Net income growth (1Y) -83.5% –
Net income CAGR (3Y) 51.8% –
EPS growth (1Y) -94.7% –
EPS CAGR (3Y) 28.9% –
Operating cash flow growth (1Y) 15.0% –
Operating cash flow CAGR (3Y) 30.5% –
Free cash flow growth (1Y) 15.7% –
Free cash flow CAGR (3Y) 30.7% –

Profitability

14 metrics
MetricSRADXTLB
Gross margin – –
EBITDA margin -15.4% –
Operating margin – –
Pretax margin 1.4% –
Net margin 1.2% –
FCF margin 31.6% –
Operating cash flow margin 31.0% –
Return on equity 2.1% –
Return on assets 0.7% –
Return on invested capital -8.6% –
Return on capital employed -3.5% –
Asset turnover 0.5x –
Cash conversion (OCF / net income) 25.1x –
Stock comp / revenue 4.2% –

Financial Health

11 metrics
MetricSRADXTLB
Debt / assets 0.4% 83.1%
Debt / equity 0.0x -0.5x
Net debt / EBITDA 1.4x –
Debt / FCF 0.0x –
Liabilities / assets 69.5% 253.0%
Equity / assets 30.5% -153.0%
Interest coverage -0.8x –
Current ratio 1.0x 0.4x
Quick ratio 0.9x 0.4x
Cash ratio 0.6x 0.2x
Altman Z-score 1.78 –

Shareholder Returns

7 metrics
MetricSRADXTLB
Dividend yield – –
Net buyback yield -1.0% –
Shareholder yield -1.0% –
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusSRADXTLB
Forward P/E 48.5xFY2026 –
EPS, next fiscal year $0.26FY2026 –
EPS growth, next FY -27.8%FY2026 –
EPS growth, the year after +100.0% –
Revenue, next fiscal year $1.65BFY2026 –
Revenue growth, next FY +8.4%FY2026 –
Revenue growth, the year after +10.8% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersSRADXTLB
Held by institutions 17.8% –
Institutions holding 151 –
Change in shares held, QoQ -2.8% –
Institutions buying 88 –
Institutions selling 42 –
Buyers to sellers 2.10 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

SRADXTLB
SRAD 1.00 0.03
XTLB 0.03 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, SRAD and XTLB?

Sportradar Group AG (SRAD) is the largest by market capitalisation: Sportradar Group AG (SRAD) $12.65B, Xtl Biopharmaceuticals (XTLB) $16.22M.

Which stock has performed better?

Over the past year Sportradar Group AG (SRAD) returned the most: Sportradar Group AG (SRAD) -53.4%, Xtl Biopharmaceuticals (XTLB) -63.0%. Over five years, Sportradar Group AG (SRAD) compounded fastest (Sportradar Group AG (SRAD) -9.0%/yr, Xtl Biopharmaceuticals (XTLB) -34.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Sportradar Group AG (SRAD) has been the steadiest (Sportradar Group AG (SRAD) 56.6%, Xtl Biopharmaceuticals (XTLB) 108.9%). Volatility measures how widely the price swings, not the risk of the business.

Do SRAD and XTLB move together?

Their daily returns over the past year have a correlation of 0.03, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, SRAD and XTLB?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Sportradar Group AG (SRAD) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.